Literature DB >> 33813933

Multivariate Generalized Linear Mixed-Effects Models for the Analysis of Clinical Trial-Based Cost-Effectiveness Data.

Felix Achana1,2,3, Daniel Gallacher3, Raymond Oppong4, Sungwook Kim1, Stavros Petrou1,2, James Mason2, Michael Crowther5,6.   

Abstract

Economic evaluations conducted alongside randomized controlled trials are a popular vehicle for generating high-quality evidence on the incremental cost-effectiveness of competing health care interventions. Typically, in these studies, resource use (and by extension, economic costs) and clinical (or preference-based health) outcomes data are collected prospectively for trial participants to estimate the joint distribution of incremental costs and incremental benefits associated with the intervention. In this article, we extend the generalized linear mixed-model framework to enable simultaneous modeling of multiple outcomes of mixed data types, such as those typically encountered in trial-based economic evaluations, taking into account correlation of outcomes due to repeated measurements on the same individual and other clustering effects. We provide new wrapper functions to estimate the models in Stata and R by maximum and restricted maximum quasi-likelihood and compare the performance of the new routines with alternative implementations across a range of statistical programming packages. Empirical applications using observed and simulated data from clinical trials suggest that the new methods produce broadly similar results as compared with Stata's merlin and gsem commands and a Bayesian implementation in WinBUGS. We highlight that, although these empirical applications primarily focus on trial-based economic evaluations, the new methods presented can be generalized to other health economic investigations characterized by multivariate hierarchical data structures.

Entities:  

Keywords:  cluster randomised controlled trials; cost-effectiveness analysis; economic evaluation alongside randomised controlled trials; multicentre and multinational randomised controlled trials

Year:  2021        PMID: 33813933      PMCID: PMC8295965          DOI: 10.1177/0272989X211003880

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  20 in total

1.  Using multilevel models for assessing the variability of multinational resource use and cost data.

Authors:  Richard Grieve; Richard Nixon; Simon G Thompson; Charles Normand
Journal:  Health Econ       Date:  2005-02       Impact factor: 3.046

2.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

3.  Estimating marginal and incremental effects on health outcomes using flexible link and variance function models.

Authors:  Anirban Basu; Paul J Rathouz
Journal:  Biostatistics       Date:  2005-01       Impact factor: 5.899

4.  Cost-effectiveness analysis for multinational clinical trials.

Authors:  Eleanor M Pinto; Andrew R Willan; Bernie J O'Brien
Journal:  Stat Med       Date:  2005-07-15       Impact factor: 2.373

5.  Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance.

Authors:  Raymond Oppong; Richard D Smith; Paul Little; Theo Verheij; Christopher C Butler; Herman Goossens; Samuel Coenen; Michael Moore; Joanna Coast
Journal:  Br J Gen Pract       Date:  2016-07-11       Impact factor: 5.386

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  The Development and validation of a self-administered quality-of-life outcome measure for young, active patients with symptomatic hip disease: the International Hip Outcome Tool (iHOT-33).

Authors:  Nicholas G H Mohtadi; Damian R Griffin; M Elizabeth Pedersen; Denise Chan; Marc R Safran; Nicholas Parsons; Jon K Sekiya; Bryan T Kelly; Jason R Werle; Michael Leunig; Joseph C McCarthy; Hal D Martin; J W Thomas Byrd; Marc J Philippon; Robroy L Martin; Carlos A Guanche; John C Clohisy; Thomas G Sampson; Mininder S Kocher; Christopher M Larson
Journal:  Arthroscopy       Date:  2012-05       Impact factor: 4.772

8.  Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial.

Authors:  Paul Little; Beth Stuart; Michael Moore; Samuel Coenen; Christopher C Butler; Maciek Godycki-Cwirko; Artur Mierzecki; Slawomir Chlabicz; Antoni Torres; Jordi Almirall; Mel Davies; Tom Schaberg; Sigvard Mölstad; Francesco Blasi; An De Sutter; Janko Kersnik; Helena Hupkova; Pia Touboul; Kerenza Hood; Mark Mullee; Gilly O'Reilly; Curt Brugman; Herman Goossens; Theo Verheij
Journal:  Lancet Infect Dis       Date:  2012-12-19       Impact factor: 25.071

9.  Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice.

Authors:  Edmond S-W Ng; Karla Diaz-Ordaz; Richard Grieve; Richard M Nixon; Simon G Thompson; James R Carpenter
Journal:  Stat Methods Med Res       Date:  2013-12-16       Impact factor: 3.021

10.  Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials.

Authors:  Manuel Gomes; Edmond S-W Ng; Richard Grieve; Richard Nixon; James Carpenter; Simon G Thompson
Journal:  Med Decis Making       Date:  2011-10-19       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.